Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 7,773 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo; placebo comparator condition Clear all
Withdrawn Phase 2 Interventional

Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease

NCT02500784
View directory record Official record
Conditions
Alzheimer's Disease, Cognitive Dysfunction
Interventions
Formoterol A, Formoterol B (placebo)
Drug · Other
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

NCT04430855
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 16, 2026, 9:16 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

NCT07116889
View directory record Official record
Conditions
Asthma, COPD (Chronic Obstructive Pulmonary Disease)
Interventions
GB-0895 (SC), Placebo (SC)
Biological · Drug
Lead sponsor
Generate Biomedicines
Industry
Eligibility
18 Years to 80 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
DeLand, Florida • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Phase 2 Interventional

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

NCT01912534
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Valsartan, Placebo
Drug
Lead sponsor
Carelon Research
Other
Eligibility
8 Years to 45 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Stanford, California • Aurora, Colorado • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Not applicable Interventional Results available

Oxytocin and Approach-avoid in Grief

NCT04505904
View directory record Official record
Conditions
Prolonged Grief Disorder, Bereavement
Interventions
Syntocinon, Placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
55 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

NCT02725515
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
XmAb5871, Placebo to match XmAb5871
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
La Jolla, California • Loma Linda, California • San Leandro, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 16, 2026, 9:16 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

NCT07804615
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder)
Interventions
VIM0423, VIM0423 Placebo
Drug
Lead sponsor
Vima Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
29
States / cities
Scottsdale, Arizona • Murrieta, California • Stamford, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Phase 3 Interventional

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients

NCT00561093
View directory record Official record
Conditions
Hypoalbuminemia, Protein-energy Malnutrition, Inflammation, Oxidative Stress, Chronic Kidney Disease (CKD) Hemodialysis
Interventions
pentoxiphylline, Nepro, anti-inflammatory module (similar to Oxepa), Placebo pill imitating pentoxiphylline, Placebo to imitate Nepro, Placebo to imitate anti-inflammatory module (similar to Oxepa)
Drug · Dietary Supplement
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Irvine, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 16, 2026, 9:16 PM EDT
Terminated Phase 2 Interventional Results available

Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder

NCT00805493
View directory record Official record
Conditions
Bipolar Disorder, Anxiety Disorders, Bipolar Affective Disorder, Bipolar Depression
Interventions
Riluzole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
9 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan

NCT00748215
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Colorectal Cancer, Diarrhea
Interventions
calcium aluminosilicate anti-diarrheal, placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 16, 2026, 9:16 PM EDT
Withdrawn Not applicable Interventional

Mindfulness Intervention and Symptom Variability in Hearing

NCT04281225
View directory record Official record
Conditions
Hearing Loss
Interventions
Attention to Variability (ATV), Placebo
Behavioral · Other
Lead sponsor
Harvard University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Phase 1 Interventional

Vigabatrin Ph 1 Cocaine Interaction Study

NCT00626834
View directory record Official record
Conditions
Cocaine Addiction
Interventions
Vigabatrin, Matching placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Phase 2 Interventional

Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

NCT03304821
View directory record Official record
Conditions
Peripheral Artery Disease (PAD)
Interventions
GM-CSF, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 85 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Safety and Tolerability Study of TML-6 in Healthy and Elderly Volunteers for Alzheimer's Disease Treatment

NCT06562114
View directory record Official record
Conditions
Healthy
Interventions
TML-6 Granules, Placebo
Drug
Lead sponsor
Merry Life Biomedical Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Not applicable Interventional

Study of Fluoxetine in Adults With Autistic Disorder

NCT00027404
View directory record Official record
Conditions
Autistic Disorder
Interventions
Fluoxetine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

NCT00499655
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
erlotinib hydrochloride, celecoxib, placebo, laboratory biomarker analysis, immunohistochemistry staining method, fluorescence in situ hybridization, mutation analysis, protein expression analysis, gene expression analysis
Drug · Other · Genetic
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 16, 2026, 9:16 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer

NCT03927885
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Waiting List
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder

NCT00149799
View directory record Official record
Conditions
Anxiety Disorders, Somatoform Disorders
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 16, 2026, 9:16 PM EDT
Terminated Phase 2 Interventional Results available

Digoxin In Treatment of Alcohol Associated Hepatitis

NCT05014087
View directory record Official record
Conditions
Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
Interventions
Intravenous digoxin
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 16, 2026, 9:16 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

NCT05053152
View directory record Official record
Conditions
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Fluciclovine F18, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography, PSMA PET Scan, Relugolix, Stereotactic Body Radiation Therapy
Procedure · Other · Drug + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2034
U.S. locations
242
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 192 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease

NCT04799158
View directory record Official record
Conditions
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Anniston, Alabama • Athens, Alabama • Huntsville, Alabama + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance

NCT00443755
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome
Interventions
metformin, pioglitazone, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC

NCT01401517
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
sodium nitrite
Drug
Lead sponsor
TheraVasc Inc.
Industry
Eligibility
35 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Aurora, Colorado • Atlanta, Georgia • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 16, 2026, 9:16 PM EDT
Completed Not applicable Interventional

Intellectual Enrichment to Build Cognitive Reserve in MS

NCT01978574
View directory record Official record
Conditions
Cognitive Impairment in Multiple Sclerosis
Interventions
Intellectual Enrichment daily activities, Intellectual Enrichment documentary videos
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
25 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 16, 2026, 9:16 PM EDT